Moxibustion for weight loss and diabetes: what the research says
'Moxa for weight loss' is a common search. What meta-analyses report on moxibustion for obesity, type 2 diabetes, diabetic peripheral neuropathy and diabetic foot — and why people with diabetic neuropathy face a high burn risk.
Short answer: the cited obesity review studied moxibustion combined with other interventions, not a moxa stick alone [2]. A review of type 2 diabetes said evidence was too sparse and weak for an effectiveness conclusion [3]. Neuropathy and diabetic-foot reviews reported promising pooled numbers but also substantial uncertainty, especially about harms [4][5]. These are three distinct clinical questions, not one general “moxa for diabetes” result.
Warning: diabetic neuropathy can reduce the ability to feel heat or pain in the feet [1]. A burning product on numb or wounded skin can cause an unnoticed injury. Do not apply moxa to numb feet or a diabetic foot wound; seek advice from the diabetes care team.
Weight loss and obesity
Searches such as “moxa stick for weight loss” are common [6].
| Source | Finding | Caveat |
|---|---|---|
| Systematic review, 2024 [2] | Eleven trials, 761 participants; combined moxibustion groups had lower weight, BMI and waist circumference | Other methods included acupuncture, embedding, herbs and diet; most trials had high or unclear bias risk; hip circumference and waist-to-hip ratio were not significantly changed |
| Meta-analysis, 2022 [7] | Pooled acupuncture and moxibustion trials for adult simple obesity reported favourable weight-related measures | The abstract calls included studies low quality and does not isolate one retail moxa format |
| Obese-PCOS network meta-analysis, 2025 [8] | Moxibustion plus catgut embedding ranked well for fasting glucose-related measures | The population had polycystic ovary syndrome; glucose markers are not a direct weight-loss result, and the combined treatment does not isolate moxa |
The first review’s reported weight mean difference of −3.32 concerns the pooled combination comparisons, not a predicted number of kilograms for a new buyer. Its BMI and waist-circumference pools had substantial between-study variation, and two other size measures were not significantly different [2]. The PCOS analysis is about a particular endocrine population and metabolic measures. A high ranking in a treatment network does not establish that a smokeless moxa stick produces weight loss [8]. The available cited summaries do not justify advertising moxa alone as a weight-loss product.
Type 2 diabetes and complications
| Condition | Source | Finding | Caveat |
|---|---|---|---|
| Type 2 diabetes | Systematic review, 2011 [3] | Authors could not conclude effectiveness for blood-glucose control | Few trials, low methodological quality and mixed comparators, including medicine and acupuncture |
| Diabetic peripheral neuropathy | Meta-analysis, 2020 [4] | Eleven trials, 927 participants; pooled nerve-conduction measures favoured moxibustion groups | Only one study reported no adverse reactions; the other ten did not report adverse events, so safety cannot be inferred |
| Diabetic foot | Meta-analysis, 2024 [5] | Twelve trials, 1,196 participants; pooled healing-time and other wound measures differed versus controls | Authors require further research on both benefit and harm before acceptance as evidence-based care |
Blood glucose, nerve function and wound healing are different outcomes
The 2011 review evaluated blood-glucose control in type 2 diabetes. Its included trials compared one-time moxibustion with a drug, moxa added to conventional treatment with conventional treatment, and moxa or moxa-plus-acupuncture with other approaches. The reviewers’ conclusion was not that a particular moxa product lowers glucose; they said trial scarcity and quality made an effectiveness conclusion difficult [3]. Readers should not substitute a symptom score, a product description or a traditional diagnostic label for measured glucose or HbA1c outcomes.
The 2020 neuropathy review pooled motor and sensory nerve-conduction measures. Its abstract uses favourable language about possible effectiveness and safety, but its adverse-event reporting is a major limitation: ten of eleven studies did not mention adverse events. “Not reported” is an unknown outcome, not a zero-event count [4]. The 2024 diabetic-foot review deals with people who already have foot disease and pooled wound outcomes. It explicitly says more research on benefits and harms is needed before treating the method as evidence-based care [5]. Neither review licenses unsupervised heat application to a foot with reduced sensation or a wound.
Why neuropathy raises the burn risk
The moxibustion safety review found that burns occurred mostly in people who could not feel or report heat, including those with sensory disabilities [9]. CDC explains that diabetic nerve damage can reduce the ability to feel pain, heat or cold in the feet, allowing small injuries to go unnoticed and worsen [1]. Clinic handouts warn against using moxa on areas without normal sensation [10]. This is a direct reason to put a safety decision ahead of a product-format comparison. A low-smoke label changes nothing about the need to account for heat and skin condition. The page is an evidence map, not a diabetes or weight-management plan.
Related pages
FAQ: related questions
Does moxa help you lose weight?
An eleven-trial review reported lower body weight, BMI and waist circumference for moxibustion combined with other interventions; most trials had high or unclear bias risk. It cannot establish that moxa alone produces weight loss.
Is moxibustion safe for people with diabetes?
Diabetic neuropathy can reduce the ability to feel heat or pain in the feet, increasing the risk of unnoticed injury. In one eleven-trial neuropathy review, ten studies did not report adverse events at all; that is not proof of safety. Do not apply a burning product to numb or wounded skin; seek advice from the diabetes care team.
Sources for this page
- CDC Your Feet and Diabetes. www.cdc.gov/diabetes/diabetes-complications/diabetes-and-you
- Kim et al. Effect of Moxibustion Combined with Other Interventions on Body Weight Reduction in the Treatment of Obesity: A Systematic Review and Meta-Analysis. J Integr Complement Med 2024. pubmed.ncbi.nlm.nih.gov/38099954/
- Kim et al. Moxibustion for managing type 2 diabetes mellitus: a systematic review. Chin J Integr Med 2011. pubmed.ncbi.nlm.nih.gov/21826591/
- Tan et al. Moxibustion for the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis following PRISMA guidelines. Medicine (Baltimore) 2020. pubmed.ncbi.nlm.nih.gov/32991431/
- Ji et al. Treatment of diabetic foot with moxibustion: Clinical evidence from meta-analysis. Int Wound J 2024. pubmed.ncbi.nlm.nih.gov/38361252/
- Moxa Sourcing analysis of public search data (Google 'People also ask', autocomplete, AI Overviews; US, UK, AU and Arabic markets) and marketplace listings, November 2026.
- Yin et al. Efficacy of acupuncture and moxibustion therapy for simple obesity in adults: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2022. pubmed.ncbi.nlm.nih.gov/36316908/
- Yu et al. Effectiveness of acupuncture and moxibustion therapy on glycolipid metabolism in patients with obese-type polycystic ovarian syndrome: A systematic review and network meta-analysis. Medicine (Baltimore) 2025. pubmed.ncbi.nlm.nih.gov/40527787/
- Safety of Moxibustion: A Systematic Review of Case Reports (PMC4058265). pmc.ncbi.nlm.nih.gov/articles/PMC4058265/
- Smokeless Moxa home instructions (Olympic Acupuncture). olympicacupuncture.com/acu/wellness-tips/smokeless-moxa/
Last reviewed: . Editorial note: this guide re-edits published sources; it does not provide medical advice or new research.
Moxa Sourcing
Need a sourcing brief?
Moxa Sourcing helps brands and clinics compare product formats and samples, plan private-label packaging and coordinate export handoff. Start with your market, quantity and packaging goals.
What details help us start?
Share the format, market, quantity, packaging, destination and expected timing.
